Financial Data and Key Metrics Changes - Q4 2025 revenue was $59.9 million, up 21.3% year-over-year, while full year revenue increased 20.2% to $225.2 million [5][18] - Adjusted EBITDA grew 41% to $27.9 million for the full year, with adjusted EBITDA margin improving 180 basis points to 12.4% [5][26] - Net loss for Q4 was $13.2 million, or $0.28 per share, compared to net income of $500,000 or $0.01 per share in Q4 2024 [24] Business Line Data and Key Metrics Changes - Strong growth was observed across all three target markets, with double-digit growth in extremities, oral maxillofacial and head and neck, and breast markets [5][8] - In extremities, growth was supported by both traumatic and chronic procedures, while oral maxillofacial and head and neck saw high double-digit growth due to surgeon adoption of the AxoGen algorithm [8] - Breast market remains one of the fastest-growing opportunities, with increased adoption of Resensation techniques [8] Market Data and Key Metrics Changes - The company achieved significant milestones in market development, including over 100 procedures completed in the prostate market across 10 clinical sites [9] - Approximately 19.8 million additional lives gained coverage in 2025, bringing commercial coverage above 65% [15] - CMS implemented a new outpatient payment classification for nerve procedures, improving the economic profile for outpatient settings [16] Company Strategy and Development Direction - The company aims for a growth target of 15%-20% and has reached a financial inflection point, enabling greater market development efforts while generating positive cash flow [4][6] - The FDA approval of Avance establishes it as the standard of reference in nerve repair, with plans for customer engagement and payer engagement to drive coverage [13] - Continued expansion of the commercial organization is planned, with significant increases in sales representatives across all markets [10] Management's Comments on Operating Environment and Future Outlook - Management characterized the 2026 revenue growth guidance of at least 18% as prudent, emphasizing the need for careful management of customer creation processes [32] - The company expects to see meaningful clinical signals from the prostate market as nerve recovery data matures [9] - Management expressed confidence in the ability to deliver disciplined growth consistent with long-term strategy [17] Other Important Information - The company completed an upsized public offering, raising $133.3 million in net proceeds, which was used to retire a term loan facility [6] - Operating expenses increased significantly due to one-time stock-based compensation expenses related to the FDA BLA approval of Avance [21][24] - The company plans to continue expanding education programs for surgeons across various markets in 2026 [12] Q&A Session Summary Question: Guidance for the year and assumptions - Management views the 18% guidance as prudent, emphasizing the need to manage customer creation processes carefully [32] Question: CMS reimbursement and pricing context - Management noted that while payments have increased, coverage expansion is crucial for future growth [35] Question: Reaction to BLA approval - The approval has provided a new vehicle to address payer objections regarding the product's experimental status [41] Question: Sales force additions and productivity - Management indicated that while 130 sales representatives in extremities may seem sufficient, full coverage would require significantly more [50] Question: Cadence of gross margin throughout the year - Management expects gross margin pressure in Q2 due to the introduction of the biologic Avance product [55] Question: Revenue contribution from prostate market - Prostate is not expected to be a significant revenue contributor in 2026, pending clinical signals from ongoing procedures [82] Question: Long-term gross margin targets - Management plans to address long-term gross margin targets later in the year, with current guidance remaining at 74%-76% [103]

Group 1 - Stroke has a high incidence and disability rate, making it a leading health threat, despite advancements in acute vascular recanalization techniques [1] - Many stroke patients suffer from severe neurological deficits, leading to long rehabilitation processes and significant burdens on families and society [1] - Regenerative medicine, particularly stem cell therapy, offers new hope for addressing the global challenge of nerve repair [1] Group 2 - A live session featuring Dr. Huo Xiaochuan, a neurosurgeon from Capital Medical University, and Li Li, founder and chairman of Senpuri (Beijing) Cell Technology Co., will discuss the scientific principles, clinical evidence, safety boundaries, and future prospects of stem cell therapy [1] - Dr. Huo Xiaochuan is recognized for his contributions to stroke intervention and has received the Wang Zhongcheng Annual Young Physician Award [1]

Core Insights - ONWARD Medical has completed a financing round exceeding €50 million (approximately 410 million RMB) to support its mission of restoring movement to spinal cord injury patients [2] - The company has transitioned from a research-focused entity to a commercial enterprise, with plans to expand its ARC-EX system and advance clinical research for the next-generation ARC-IM system [3] Product Development - ONWARD's product ecosystem includes three core products: ARC-EX, ARC-IM, and ARC-BCI, which together cover the full spectrum from non-invasive rehabilitation to closed-loop implants [5][7] - The ARC-EX system is a transcutaneous electrical nerve stimulation device approved in the U.S. for restoring upper limb function post-spinal cord injury, while ARC-IM is an implantable system for more severe motor impairments [8] Technological Framework - ONWARD is developing a closed-loop system that integrates neural stimulation, motor feedback, and brain-computer interfaces (BCI) to create a comprehensive rehabilitation solution [8] - The company has completed five successful implant surgeries of the brain-spinal cord closed-loop system, demonstrating the potential for neural plasticity to be reactivated [9] Strategic Partnerships - Ottobock, a leading prosthetics and orthotics company, has significantly invested in ONWARD, indicating a strategic shift towards neuro-rehabilitation technologies [10][12] - This partnership is seen as a critical component in Ottobock's transition towards integrating neural reconnection with prosthetic solutions [12] Market Context - In China, the spinal cord injury patient population exceeds 1 million, with approximately 60,000 new cases annually, highlighting a growing need for effective neuro-rehabilitation technologies [13] - ONWARD's approach contrasts with many Chinese BCI companies that focus on human-machine interaction rather than functional restoration, positioning ONWARD's model as a potential reference for domestic development [13] Regulatory Environment - ONWARD's ARC-BCI has received FDA breakthrough device designation, facilitating a more streamlined regulatory pathway for its neuro-rehabilitation products [14] - The company is establishing a clear validation system through multi-center clinical trials, creating a data loop that supports its commercial strategy [16] Future Outlook - The recent financing marks a significant step for ONWARD, transitioning from technical validation to building a sustainable commercial framework in the neuro-rehabilitation sector [18] - The integration of capital and engineering efforts is expected to redefine the human movement system, emphasizing the importance of restoring autonomy to patients [19]